Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?Memo · 2018
   Review
2. Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report.Oncology letters · 2017
   Article
3. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.Clinical and molecular hepatology · 2015
   Article
4. Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.World journal of gastroenterology · 2015
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as